BiotechTube
BIOS Health

BIOS Health

Cambridge, United Kingdom· Est.
bios.health
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15.5M

Overview

BIOS Health is developing a foundational neural interface and AI platform to translate neural signals into targeted digital therapeutics, starting with cardiovascular disease. The company's core technology enables real-time reading and writing of neural data to correct faulty organ signals, positioning it at the forefront of bioelectronic medicine. With a strong scientific advisory board and operations in Cambridge and Montreal, BIOS is advancing its Autonomic Therapy Initiative and Neural Dosing Platform through partnerships and internal R&D. The long-term vision is to establish a new infrastructure for neural digital therapies across multiple chronic conditions.

Cardiovascular

Technology Platform

Proprietary neural interfaces and AI software platform capable of bidirectional (read/write) communication with the peripheral nervous system to decode neural 'code' and deliver personalized neuromodulation therapies in real-time.

Funding History

3
Total raised:$15.5M
Series A$12M
Grant$1.2M
Seed$2.3M

Opportunities

The massive unmet need in cardiovascular disease and the nascent state of bioelectronic medicine present a first-mover opportunity to establish a new treatment paradigm.
The platform's ability to provide real-time neural efficacy data for pharmaceuticals creates a high-value partnership model with large pharma companies, offering a faster, more precise alternative to traditional drug development cycles.

Risk Factors

The core technology faces extreme technical hurdles in achieving stable, long-term, and precise bidirectional neural interfacing.
As a novel therapeutic modality, the company faces uncertain and potentially lengthy regulatory pathways for approval and reimbursement.
Competition from large, well-resourced medtech and pharma companies entering the bioelectronics space is intensifying.

Competitive Landscape

BIOS operates in the competitive bioelectronic medicine space, facing rivals like Setpoint Medical (now part of Medtronic), Galvani Bioelectronics (GSK-Verily JV), and NeuroOne. Its key differentiator is its emphasis on a closed-loop, AI-driven platform for real-time neural data reading and writing, aiming for a more dynamic and personalized approach compared to static neuromodulation devices.

More companies in United Kingdom →